Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
24 mars 2021 08h28 HE
|
Revive Therapeutics Ltd.
TORONTO, March 24, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
19 mars 2021 07h30 HE
|
Revive Therapeutics Ltd.
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
26 févr. 2021 09h50 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
26 févr. 2021 08h33 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Acquires Unique Psilocybin Assets
17 févr. 2021 09h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
12 févr. 2021 09h42 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program
11 févr. 2021 07h28 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
09 févr. 2021 17h00 HE
|
Revive Therapeutics Ltd.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA:...
Revive Therapeutics Files Business Acquisition Report
08 févr. 2021 17h39 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR)...
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund
22 janv. 2021 11h05 HE
|
Revive Therapeutics Ltd.
TORONTO, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...